Seagen announces long-term results from Tukysa pivotal trial for HER2-positive breast cancer during the 2021 ASCO Annual Meeting
Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of… read more.
